EXCAAPE
OFFICIAL TITLE: A PHASE II CLINICAL TRIAL OF RADIUM-223 ACTIVITY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WITH ASYMPTOMATIC PROGRESSION WHILE ON ABIRATERONE ACETATE OR ENZALUTAMIDE BESIDES AR-V7 MUTATIONAL STATUS.
PROJECT DETAILS
RADIUM-223 IS INDICATED FOR THE TREATMENT OF PATIENTS WITH MCRPC WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE. HOWEVER, VERY FEW DATA HAVE BEEN REPORTED IN PATIENTS WITH MCRPC WHO ARE ASYMPTOMATIC OR MILDLY SYMPTOMATIC. RECENTLY, RESULTS FROM AN INTERNATIONAL EXPANDED ACCESS PROGRAM HAVE ALSO SUGGESTED A BENEFIT OF RADIUM-223 IN ASYMPTOMATIC PATIENTS WITH MCRPC. IN ADDITION, THE MECHANISM OF ACTION OF RADIUM-223 SHOULD NOT BE CORRELATED WITH THE PRESENCE/ABSENCE OF THE AR-V7 MUTATION, ALTHOUGH THIS ISSUE HAS NOT YET BEEN EVALUATED.
THE AIM OF THIS STUDY IS TO ASSESS THE EFFICACY OF RADIUM-223 IN ASYMPTOMATIC PATIENTS WITH MCRPC, AND TO ESTABLISH THE ASSOCIATION BETWEEN AR-V7 STATUS AND RADIUM-223 ACTIVITY.
EXCAAPE AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
Recruitment closed
ESMO 2017 – DOWNLOAD THE POSTER
EXCAAPE SITES
